Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

The companies have committed to working in close collaboration to ensure a smooth transition for employees and customers.

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

WuXi AppTec agreed in December to sell the U.S. and United Kingdom operations of its WuXi Advanced Therapies unit, which include a major presence at the Philadelphia Navy Yard, to New York health ...

(Yicai) Jan. 14 -- WuXi AppTec’s shares rose after the pharmaceutical services provider sold stakes in an affiliated company, ...

WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...